As filed with the Securities and Exchange Commission on April 11, 1997
                        Registration No. 333- __________
         --------------------------------------------------------------


                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                    FORM S-8
                             REGISTRATION STATEMENT
                                      UNDER
                           THE SECURITIES ACT OF 1933

                        Interneuron Pharmaceuticals, Inc.
 -------------------------------------------------------------------------------

             (Exact name of registrant as specified in its charter)

                                    Delaware
 -------------------------------------------------------------------------------

         (State or other jurisdiction of incorporation or organization)

                                    043047911
 -------------------------------------------------------------------------------

                      (I.R.S. employer identification no.)

           One Ledgemont Center, 99 Hayden Avenue, Lexington, MA 02173
 -------------------------------------------------------------------------------

                    (Address of principal executive offices)

                    1994 Long-Term Incentive Plan, as amended
                              (Full title of plan)

                        Glenn L. Cooper, M.D., President
                        Interneuron Pharmaceuticals, Inc.
                              One Ledgemont Center
                                99 Hayden Avenue
                         Lexington, Massachusetts 02173
                     (Name and address of agent for service)

                                 (617) 861-8444
          (Telephone number, including area code, of agent for service)

                                    Copy to:
                               Jill M. Cohen, Esq.
                      Bachner, Tally, Polevoy & Misher LLP
                               380 Madison Avenue
                               New York, NY 10017







                         CALCULATION OF REGISTRATION FEE

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------------

                                        Proposed          Proposed
                                        Maximum           Maximum
                                        Offering          Aggregate                               Amount of
Title of Securities                       to be           Price Per        Offering             Registration
 to be Registered                       Registered          Share(1)         Price                   Fee
 ----------------                       ----------          --------         -----                   ---
<S>                                     <C>               <C>              <C>                  <C>
Common Stock, $.001
  par value                             3,000,000         $18.69           $56,070,000          $16,989.21
-------------------------------------------------------------------------------------------------------------------
</TABLE>

(1)      Estimated  in  accordance  with Rule  457(h)  solely for the purpose of
         calculating the registration fee. The price shown is the average of the
         high and low prices of the Common Stock on April 8, 1997 as reported on
         the Nasdaq National Market.








                                     PART II


               INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3.        Incorporation of Documents by Reference

               The Registration Statement on Form S-8 (File No. 33-75826), filed
by Interneuron  Pharmaceuticals,  Inc. (the  "Registrant") on July 19, 1995, and
the  documents  listed  below are hereby  incorporated  by  reference  into this
Registration  Statement,  and all documents subsequently filed by the Registrant
pursuant to Sections 13(a),  13(c), 14 and 15(d) of the Securities  Exchange Act
of 1934, as amended,  prior to the filing of a  post-effective  amendment  which
indicates that all securities  offered have been sold or which  deregisters  all
securities  then  remaining  unsold,  shall  be  deemed  to be  incorporated  by
reference in this Registration  Statement and to be part hereof from the date of
filing such documents:

               (a)    The  Registrant's  Annual  Report on Form  10-K  (File No.
                      0-18728) for its fiscal year ending September 30, 1996;

               (b)    The Registrant's definitive Proxy Statement, dated January
                      28,  1997,  as filed  with  the  Securities  and  Exchange
                      Commission  (the  "Commission")  in  connection  with  the
                      Company's Annual Meeting of Stockholders  held on March 5,
                      1997;

               (c)    The  Registrant's  quarterly  report  on Form 10-Q for the
                      quarterly period ended December 31, 1996;

               (d)    The  Registrant's  report  on Form 8-K as  filed  with the
                      Commission on February 18, 1997;

               (e)    The  Registrant's  report  on Form 8-K as  filed  with the
                      Commission on March 14, 1997; and

               (f)    The  Registrant's   Registration  Statement  on  Form  8-A
                      declared   effective   on  March  8,  1990,   as  amended,
                      registering the Common Stock,  $.001 par value,  under the
                      Securities Exchange Act of 1934, as amended.

Item 8.        Exhibits

               5.1    Opinion of  Bachner,  Tally,  Polevoy & Misher  LLP,  with
                      respect  to  the  legality  of  the  Common  Stock  to  be
                      registered hereunder

               10.65  1994 Long-Term Incentive Plan, as amended

               23.1   Consent of Coopers & Lybrand L.L.P.

               23.2   Consent of Bachner, Tally, Polevoy & Misher LLP (contained
                      in Exhibit 5.1)







                                   SIGNATURES

               Pursuant to the  requirements  of the Securities Act of 1933, the
registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-8 and has duly caused this registration
statement  to be  signed  on its  behalf  by  the  undersigned,  thereunto  duly
authorized, in the City of Lexington, State of Massachusetts, on the 11th day of
April, 1997.

                                           INTERNEURON PHARMACEUTICALS, INC.


                                           By: /s/ Glenn L. Cooper
                                               -------------------------------
                                              Glenn L. Cooper, M.D., President
                                              and Chief Executive Officer
                                              (Principal Executive Officer)


               Pursuant to the  requirements of the Securities Act of 1933, this
registration  statement  has been signed below by the  following  persons in the
capacities and as of the date indicated.

<TABLE>
<CAPTION>
                 <S>                              <C>                                   <C> 
              Signature                          Title                                  Date
              ---------                          -----                                  ----

   /s/ Glenn L. Cooper                      President and Chief Executive               April  11, 1997
-----------------------------------          Officer and Director
Glenn L. Cooper , M.D.                       (Principal Executive Officer)

                                            Chairman of the Board of                    April    , 1997
-----------------------------------          Directors
Lindsay A. Rosenwald, M.D.         

 /s/ Harry J. Gray                          Director                                    April  11, 1997
-----------------------------------
Harry J. Gray

 /s/ Alexander M. Haig                      Director                                    April  11, 1997
-----------------------------------
Alexander M. Haig, Jr.

 /s/ Peter Barton Hutt                      Director                                    April  11, 1997
-----------------------------------
Peter Barton Hutt

 /s/ Malcolm Morville                       Director                                    April  11, 1997
-----------------------------------
Malcolm Morville, Ph.D.

 /s/ Robert K. Mueller                      Director                                    April  11, 1997
-----------------------------------
Robert K. Mueller







 /s/ Lee J. Schroeder                       Director                                    April  11, 1997
-----------------------------------
Lee J. Schroeder

 /s/ David B. Sharrock                      Director                                    April  11, 1997
-----------------------------------
David B. Sharrock

 /s/ Richard Wurtman                        Director                                    April  11, 1997
-----------------------------------
Richard Wurtman, M.D.

/s/ Dale Ritter                              Vice President, Corporate Controller       April  11, 1997
-----------------------------------          and Chief Accounting Officer
Dale Ritter                                  (Principal Accounting Officer)

</TABLE>








                                INDEX TO EXHIBITS
                        INTERNEURON PHARMACEUTICALS, INC.


Exhibit
  No.             Description
  ---             -----------

5.1               Opinion of Bachner, Tally, Polevoy & Misher LLP,
                  with respect to the legality of the Common
                  Stock to be registered hereunder

10.65             1994 Long-Term Incentive Plan, as amended

23.1              Consent of Coopers & Lybrand L.L.P.

23.2              Consent of Bachner, Tally, Polevoy & Misher LLP
                  (contained in Exhibit 5)
[{"type": "S-8", "sequence": "1", "description": "FORM S-8", "secsgml_size_bytes": 10204}]
{"company-data": {"conformed-name": "INTERNEURON PHARMACEUTICALS INC", "cik": "0000854222", "assigned-sic": "2834", "irs-number": "043047911", "state-of-incorporation": "DE", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-24969", "film-number": "97578565"}, "business-address": {"street1": "ONE LEDGEMONT CENTER", "street2": "99 HAYDEN AVE", "city": "LEXINGTON", "state": "MA", "zip": "02173", "phone": "6178618444"}, "mail-address": {"street1": "ONE LEDGEMONT CENTER", "street2": "99 HAYDEN AVE", "city": "LEXINGTON", "state": "MA", "zip": "02173"}}
As filed with the Securities and Exchange Commission on April 11, 1997
                        Registration No. 333- __________
         --------------------------------------------------------------

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM S-8
                             REGISTRATION STATEMENT
                                      UNDER
                           THE SECURITIES ACT OF 1933

                        Interneuron Pharmaceuticals, Inc.
 -------------------------------------------------------------------------------

             (Exact name of registrant as specified in its charter)

                                    Delaware
 -------------------------------------------------------------------------------

         (State or other jurisdiction of incorporation or organization)

                                    043047911
 -------------------------------------------------------------------------------

                      (I.R.S. employer identification no.)

           One Ledgemont Center, 99 Hayden Avenue, Lexington, MA 02173
 -------------------------------------------------------------------------------

                    (Address of principal executive offices)

                    1994 Long-Term Incentive Plan, as amended
                              (Full title of plan)

                        Glenn L. Cooper, M.D., President
                        Interneuron Pharmaceuticals, Inc.
                              One Ledgemont Center
                                99 Hayden Avenue
                         Lexington, Massachusetts 02173
                     (Name and address of agent for service)

                                 (617) 861-8444
          (Telephone number, including area code, of agent for service)

                                    Copy to:
                               Jill M. Cohen, Esq.
                      Bachner, Tally, Polevoy & Misher LLP
                               380 Madison Avenue
                               New York, NY 10017

                         CALCULATION OF REGISTRATION FEE
-------------------------------------------------------------------------------------------------------------------

                                        Proposed          Proposed
                                        Maximum           Maximum
                                        Offering          Aggregate                               Amount of
Title of Securities                       to be           Price Per        Offering             Registration
 to be Registered                       Registered          Share(1)         Price                   Fee
 ----------------                       ----------          --------         -----                   ---
Common Stock, $.001
  par value                             3,000,000         $18.69           $56,070,000          $16,989.21
-------------------------------------------------------------------------------------------------------------------
(1)      Estimated  in  accordance  with Rule  457(h)  solely for the purpose of
         calculating the registration fee. The price shown is the average of the
         high and low prices of the Common Stock on April 8, 1997 as reported on
         the Nasdaq National Market.

                                     PART II

               INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3.        Incorporation of Documents by Reference

               The Registration Statement on Form S-8 (File No. 33-75826), filed
by Interneuron  Pharmaceuticals,  Inc. (the  "Registrant") on July 19, 1995, and
the  documents  listed  below are hereby  incorporated  by  reference  into this
Registration  Statement,  and all documents subsequently filed by the Registrant
pursuant to Sections 13(a),  13(c), 14 and 15(d) of the Securities  Exchange Act
of 1934, as amended,  prior to the filing of a  post-effective  amendment  which
indicates that all securities  offered have been sold or which  deregisters  all
securities  then  remaining  unsold,  shall  be  deemed  to be  incorporated  by
reference in this Registration  Statement and to be part hereof from the date of
filing such documents:

               (a)    The  Registrant's  Annual  Report on Form  10-K  (File No.
                      0-18728) for its fiscal year ending September 30, 1996;

               (b)    The Registrant's definitive Proxy Statement, dated January
                      28,  1997,  as filed  with  the  Securities  and  Exchange
                      Commission  (the  "Commission")  in  connection  with  the
                      Company's Annual Meeting of Stockholders  held on March 5,
                      1997;

               (c)    The  Registrant's  quarterly  report  on Form 10-Q for the
                      quarterly period ended December 31, 1996;

               (d)    The  Registrant's  report  on Form 8-K as  filed  with the
                      Commission on February 18, 1997;

               (e)    The  Registrant's  report  on Form 8-K as  filed  with the
                      Commission on March 14, 1997; and

               (f)    The  Registrant's   Registration  Statement  on  Form  8-A
                      declared   effective   on  March  8,  1990,   as  amended,
                      registering the Common Stock,  $.001 par value,  under the
                      Securities Exchange Act of 1934, as amended.

Item 8.        Exhibits

               5.1    Opinion of  Bachner,  Tally,  Polevoy & Misher  LLP,  with
                      respect  to  the  legality  of  the  Common  Stock  to  be
                      registered hereunder

               10.65  1994 Long-Term Incentive Plan, as amended

               23.1   Consent of Coopers & Lybrand L.L.P.

               23.2   Consent of Bachner, Tally, Polevoy & Misher LLP (contained
                      in Exhibit 5.1)

                                   SIGNATURES

               Pursuant to the  requirements  of the Securities Act of 1933, the
registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-8 and has duly caused this registration
statement  to be  signed  on its  behalf  by  the  undersigned,  thereunto  duly
authorized, in the City of Lexington, State of Massachusetts, on the 11th day of
April, 1997.

                                           INTERNEURON PHARMACEUTICALS, INC.

                                           By: /s/ Glenn L. Cooper
                                               -------------------------------
                                              Glenn L. Cooper, M.D., President
                                              and Chief Executive Officer
                                              (Principal Executive Officer)

               Pursuant to the  requirements of the Securities Act of 1933, this
registration  statement  has been signed below by the  following  persons in the
capacities and as of the date indicated.
Signature                          Title                                  Date
              ---------                          -----                                  ----

   /s/ Glenn L. Cooper                      President and Chief Executive               April  11, 1997
-----------------------------------          Officer and Director
Glenn L. Cooper , M.D.                       (Principal Executive Officer)

                                            Chairman of the Board of                    April    , 1997
-----------------------------------          Directors
Lindsay A. Rosenwald, M.D.         

 /s/ Harry J. Gray                          Director                                    April  11, 1997
-----------------------------------
Harry J. Gray

 /s/ Alexander M. Haig                      Director                                    April  11, 1997
-----------------------------------
Alexander M. Haig, Jr.

 /s/ Peter Barton Hutt                      Director                                    April  11, 1997
-----------------------------------
Peter Barton Hutt

 /s/ Malcolm Morville                       Director                                    April  11, 1997
-----------------------------------
Malcolm Morville, Ph.D.

 /s/ Robert K. Mueller                      Director                                    April  11, 1997
-----------------------------------
Robert K. Mueller

 /s/ Lee J. Schroeder                       Director                                    April  11, 1997
-----------------------------------
Lee J. Schroeder

 /s/ David B. Sharrock                      Director                                    April  11, 1997
-----------------------------------
David B. Sharrock

 /s/ Richard Wurtman                        Director                                    April  11, 1997
-----------------------------------
Richard Wurtman, M.D.

/s/ Dale Ritter                              Vice President, Corporate Controller       April  11, 1997
-----------------------------------          and Chief Accounting Officer
Dale Ritter                                  (Principal Accounting Officer)
INDEX TO EXHIBITS
                        INTERNEURON PHARMACEUTICALS, INC.

Exhibit
  No.             Description
  ---             -----------

5.1               Opinion of Bachner, Tally, Polevoy & Misher LLP,
                  with respect to the legality of the Common
                  Stock to be registered hereunder

10.65             1994 Long-Term Incentive Plan, as amended

23.1              Consent of Coopers & Lybrand L.L.P.

23.2              Consent of Bachner, Tally, Polevoy & Misher LLP
                  (contained in Exhibit 5)